<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801658</url>
  </required_header>
  <id_info>
    <org_study_id>FunkSLT</org_study_id>
    <nct_id>NCT00801658</nct_id>
  </id_info>
  <brief_title>Efficacy of SLT in Patients With Insufficient IOP Control Under Maximum Tolerated Drug Therapy (Eye Drops)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ellex Medical Pty, 82 Gilbert Str., Adelaide, SA 5000</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination and follow-up of efficacy and safety of SLT in patients with unsufficient IOP&#xD;
      control despite maximum tolerated topical therapy. In addition, it will be examined whether&#xD;
      medical treatment can be reduced after the SLT procedure and whether filtering surgery - as&#xD;
      the only remaining option - may be postponed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLT (Selective Laser Trabeculoplasty) uses the Nd:YAG-Lasers (wavelength 532nm, Q-switched,&#xD;
      frequency-doubled). Thanks to the low laser energy used and the short duration of treatment,&#xD;
      only pigmented cells of the trabecular meshwork are targeted and selectively treated.&#xD;
      Neighboring, non-pigmented cells and tissue are spared collateral and thermic damage, the&#xD;
      architecture of the trabecular meshwork remains intact. The SLT procedure uses less than 1%&#xD;
      of the energy of the ALT procedure with an extremely low pulsation duration.&#xD;
&#xD;
      Several studies confirm the effective IOD reduction of SLT and rate the procedure as an&#xD;
      relatively safe and effective therapy for glaucoma. Also repeated use of the SLT procedure is&#xD;
      considered as meaningful. Meanwhile the SLT procedure is used as primary and supplementary&#xD;
      treatment of glaucoma and study confirmed that the SLT procedure was just as effective as&#xD;
      administration of Latanoprost in reducing IOD in newly-diagnosed glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date>July 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP lowering effect of SLT in a special patient group</measure>
    <time_frame>1 day, 1 , 3, 6 , 12 months postoperative</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Glaucoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>selective Laser Trabeculoplasty (SLT)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Patients with&#xD;
&#xD;
          -  primary open angle glaucoma (including normal tension glaucoma)&#xD;
&#xD;
          -  pseudoexfoliation glaucoma&#xD;
&#xD;
          -  pigment dispersion glaucoma&#xD;
&#xD;
        Exclusion criteria: previous intraocular surgery closed angle glaucoma pediatric glaucoma&#xD;
        inflammatory or uveitic glaucoma unclear view of the trabecular meshwork&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>December 3, 2008</last_update_submitted>
  <last_update_submitted_qc>December 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Dr. Jens Funk</name_title>
    <organization>University hospital zurich, eye clinic</organization>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>SLT</keyword>
  <keyword>Laser treatment</keyword>
  <keyword>IOP</keyword>
  <keyword>glaucoma treated with eye drops but IOP not controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

